Rebecca R. Hozak

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

Andrew X. Zhu, Richard S. Finn, Mary F. Mulcahy et al. · Clinical Cancer Research · 2013 · 164 citations · Full text

dad-1, an endogenous programmed cell death suppressor in Caenorhabditis elegans and vertebrates.

Asako Sugimoto, Rebecca R. Hozak, Torahiko Nakashima et al. · The EMBO Journal · 1995 · 114 citations · Full text

Transcriptional Regulation, Developmental Biology, Molecular Regulation +8

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

J. Randolph Hecht, Sara Lonardi, Johanna C. Bendell et al. · Journal of Clinical Oncology · 2021 · 102 citations · Full text

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

Josep Tabernero, Rebecca R. Hozak, Takayuki Yoshino et al. · Annals of Oncology · 2017 · 101 citations · Full text

Baculovirus inhibitor of apoptosis functions at or upstream of the apoptotic suppressor P35 to prevent programmed cell death

Gulam A. Manji, Rebecca R. Hozak, Douglas LaCount et al. · Journal of Virology · 1997 · 94 citations · Full text

Iap Function, Apoptosis, Immunology +18